Speakers

United States

Dr. Dauber is currently the Chief of Endocrinology at Children’s National Hospital. Dr. Dauber earned his MD and a Master’s degree in clinical investigation at Harvard Medical School. He completed his pediatrics residency, chief residency, and pediatric endocrinology fellowship training at Boston Children’s Hospital.

At Boston Children’s Hospital, Dr. Dauber began his research career in the laboratory of Joel Hirschhorn. Dr. Dauber’s work focuses on rare genetic causes of growth disorders and the use of next generation sequencing technologies to understand pediatric endocrine disorders. He has identified numerous genetic etiologies for short stature in addition to discovering that mutations in the MKRN3 and DLK1 genes are responsible for central precocious puberty. After his time in Boston, Dr. Dauber was the inaugural Program Director of The Cincinnati Center for Growth Disorders at Cincinnati Children’s Hospital. In 2018, Dr. Dauber moved to Washington, DC and assumed his current position of Chief of Endocrinology at Children’s National Hospital. Dr. Dauber is currently leading a clinical trial exploring the use of vosoritide in children with selected genetic causes of short stature.

In acknowledgment of his work, Dr. Dauber has earned multiple awards including young investigator awards from the Pediatric Endocrine Society, the American Society of Clinical Investigation and the European Society of Pediatric Endocrinology. In addition, he is the recipient of the Richard E. Weitzman Outstanding Early Career Investigator Award from the Endocrine Society.

MD FRSNZ
New Zealand

Ian Reid is an endocrinologist and Distinguished Professor at the University of Auckland. His research interests include calcium metabolism, vitamin D, osteoporosis and Paget’s disease. He has worked extensively in the development of the bisphosphonates for use in osteoporosis and Paget’s disease, and also on the safety and efficacy of calcium supplements, vitamin D deficiency and supplementation, and has been involved in development of most new osteoporosis treatments in the last 30 years. He is a past-president of the International Bone and Mineral Society (IBMS) and the Australian & New Zealand Bone & Mineral Society (ANZBMS), and recipient of research awards from the European Calcified Tissue Society, the American Society of Bone and Mineral Research, the ANZBMS and the New Zealand Prime Minister’s Science Prize.

Professor of Public Heath,
Department of Public Health and Primary Care, Imperial College
London & Honorary Consultant Cardiologist, Imperial College NHS Trust
United Kingdom

Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap 2021-2022, Chair for Global Council for Heart Health. National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now.

He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >120,000 citations and since 2018 has been recognised annually by Clarivate Analytics as among the top 0.1% of authors in global medicine

He lead the international development program for Inclisiran, the first siRNA-based therapy for cholesterol-lowering approved globally, in addition to playing a key role in the development program of Bempedoic Acid and PCSK9 monoclonal antibodies. He initiated the Familial Hypercholesterolaemia Studies Collaboration (FHSC), the only global registry of FH, as well as multi-national European registries such as Da Vinci, Heymans and Santorini, all of which are helping to shape global health policy

United Kingdom

Mark Gurnell is Professor of Clinical Endocrinology in Cambridge, where he is Clinical Lead for Endocrine Services.

He is Head of Section (Specialty Medicine Research & Training) in the Department of Medicine, and SubDean in the School of Clinical Medicine.

His clinical and research interests are focussed on pituitary, adrenal and thyroid disorders, with particular interests in:

• Acromegaly
• Cushing’s disease
• TSH-secreting pituitary adenomas
• Secondary adrenal insufficiency
• Primary aldosteronism

He is head of the Cambridge Endocrine Molecular Imaging Group (CEMIG) and has led the development of novel PET tracers for imaging pituitary adenomas and adrenocortical tumours, with several now in use in routine clinical practice.

He also co-leads the Cambridge REFTFTs service, which provides advice on the investigation and management of patients with unusual/atypical thyroid function test results.

He currently serves on various committees/panels, including:

• Council of the UK Society for Endocrinology (Treasurer)
• Education & Nominations Committees of the European Society of Endocrinology
• US Endocrine Society’s ESAP panel
• Pituitary Society’s Professional Education Committee
• European Board Examination in Endocrinology, Diabetes & Metabolism (Co-Chair)

He holds a number of senior appointments in medical education and chairs the the Board of the UK Medical Schools Council Assessment Alliance. He also chairs the Exam Board for the forthcoming UK Medical Licensing Assessment (MLA) Applied Knowledge Test (AKT) and has recently stepped down from the Royal College of Physicians Specialty Certificate Examination (SCE - Diabetes & Endocrinology) Exam Board.

United States

Dr. Philip Schauer is the Mary Kay and Terrell Brown endowed Professor of Metabolic Surgery at Pennington Biomedical Research Center of Louisiana State University in Baton Rouge, Louisiana. He is Director of the MetamorTM Metabolic Institute at Pennington Biomedical. He is formerly Professor of Surgery at the Cleveland Clinic Lerner College of Medicine. He is past president of the American Society for Metabolic & Bariatric Surgery (ASMBS). He is former Chair and founder of Obesity Week (2012-present) and Co-Chair of the Diabetes Surgery Summit (2007, 2015, 2019).

He is a graduate of Baylor College of Medicine in 1986. He completed surgical residency training at the University of Texas in San Antonio in 1993. He then completed one of the first fellowships in advanced laparoscopy at Duke University in 1995. He started his academic career at the University of Pittsburgh in 1995 and rose to the rank of Associate Professor of Surgery by 2004 when he was recruited to the Cleveland Clinic as Professor of Surgery and Director of Metabolic Surgery.

Dr. Schauer's clinical interests include obesity, diabetes and metabolic surgery. He has performed more than 8000 operations on 5 continents around the world for severe obesity and diabetes. His research interests include the pathophysiology of obesity and type 2 diabetes, and outcomes of metabolic surgery.

He has authored more than 400 scientific papers, 60 textbook chapters, and 3 textbooks related to obesity, bariatric/metabolic surgery and gastrointestinal surgery. He has published is work in high impact journals such as New England Journal Medicine, JAMA, Lancet, Nature, Diabetologia, Diabetes Care and others with more than 35,000 citations and a H-index of 90, highest amongst peers. He is principal investigator of the STAMPEDE trail comparing medical and surgical treatment of diabetes published in New England Journal of Medicine (2012, 2014, 2017) with more than 6000 citations and numerous awards from American Heart Association, American College of Cardiology, NIH and Wall Street Journal. He has been principal investigator on 3 NIH funded studies evaluating surgical treatment of diabetes and obesity. He is past chairman of the Bariatric Surgery Section of The Obesity Society (TOS). He has been a member of the editorial board of many scientific journals. He has been an invited speaker for more than 200 international lectures on the subject of metabolic surgery. He has trained more than 200 postgraduate surgeons and 100 fellows in advanced laparoscopic and bariatric surgery (3 Presidents of ASMBS). He holds 4 patents for medical devices. He is the recipient of the SAGES Pioneer in Surgical Endoscopy Award 2018. He is the recipient of the Cleveland Clinic 2015 Sones Award – highest honor for scientific innovation at the Cleveland Clinic.

MBBS MD FRCP
Professor/ Hon Consultant in Diabetes
Diabetes Research Centre
University of Leicester
United Kingdom

Prof Pratik Choudhary is Professor and Honorary consultant in Diabetes with a special interest in type 1 diabetes and technology. He has active clinical and research programs around education, psychology and technology in type 1 diabetes. In particular, his research uses neuroimaging to explore the mechanisms of hypoglycaemia unawareness, and the use of different strategies such as technology and behavioral interventions to restore awareness. He has been involved in a number of national and international research studies, as well as a number of national and international training and education programs for diabetes.

He is currently chair of the Diabetes Technology Network-UK, working to improve access to technology for diabetes through training, education and advocacy. He is also medical advisor to the Department of Transport, associate editor for Diabetic Medicine, Midlands Type 1 Diabetes Clinical Lead and member of the EASD Post Graduate education committee.

United States

Dr. Basaria is Professor of Medicine at Harvard Medical School, and Associate Director of the Section of Men's Health, Aging and Metabolism at the Brigham and Women's Hospital. His expertise is in the field of Male Reproduction. His research focuses on understanding cardiometabolic complications of androgen deprivation therapy in men with prostate cancer and efficacy of testosterone replacement in men with opioid-induced androgen deficiency. He provides clinical care to patients with a variety of reproductive disorders.

United Kingdom

Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine and Metabolism at Newcastle University and Newcastle Hospitals NHS Trust. He founded the Newcastle Magnetic Resonance Centre in 2006 to develop innovative research techniques for all specialists. In 2011 he showed that type 2 diabetes was a simple, reversible condition caused by excess fat inside liver and pancreas. Subsequent he has clarified the underlying pathophysiology and demonstrated complete return to normal pancreas morphology and functional beta cell capacity during long term remission. This has led to practical application in the NHS. Between 1986 and 2000, Professor Taylor developed the system now used throughout the United Kingdom for screening for diabetic eye disease, with major reduction in blindness due to diabetes across the UK. His book explaining type 2 diabetes and its reversal in simple language has been translated in several languages

United Kingdom

Professor Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust.

He trained at Queen’s Medical Centre, Nottingham and undertook his research training at the University of Nottingham and Washington University, USA. From 2000-2005 he was Editor of Diabetic Medicine.

He is currently a member of the Diabetes UK Diabetes Research Strategy Groups Management Board and UK Juvenile Diabetes Research International, UK Scientific Advisory Committee. He is currently the NIHR Clinical Research Network National Lead for Diabetes and an NIHR Senior Investigator Emeritus.

Prof Heller’s current research interests include the pathophysiological responses to hypoglycaemia and hypoglycaemia unawareness, the potential contribution and mechanisms of hypoglycaemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycaemia. He is currently Chair of the EASD International Hypoglycaemia Study Group. He also conducts research programmes concerned with developing interventions (including the DAFNE intervention) to encourage more effective diabetes self-management.

Prof Heller has authored over 200 original research articles and reviews.

MD, PhD
United States

Dr. Russell is an endocrinologist and diabetologist with 20 years of experience managing diabetes. He is the Chief Medical Officer of Beta Bioincs, Inc., a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® bionic pancreas. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™. Dr. Russell is also an Associate Professor of Medicine at Harvard Medical School (part time) and an attending physician at the Massachusetts General Hospital (MGH) Diabetes Associates in Boston where he maintains a clinical practice managing diabetes in the outpatient and inpatient settings on a part-time basis.

He received a Bachelor of Science degree in Biochemistry from Trinity University in San Antonio, and both a PhD in Biological Chemistry and an MD from the University of Texas Southwestern Medical Center in Dallas. He completed his residency training in Internal Medicine and his fellowship in Endocrinology, Diabetes, & Metabolism at the MGH, and a postdoctoral fellowship studying insulin and aging at the Joslin Diabetes Center in Boston.

Dr. Russell’s research at the MGH has been focused on the application of new technologies to improve the care of people with diabetes, including the collaboration with Dr. Ed Damiano’s research group at Boston University to develop and test a wearable bionic pancreas for automated blood glucose control in diabetes. This work led to the founding of Beta Bionics in 2015. Dr. Russell has directed nearly all of the bionic pancreas clinical trials, including 20 studies in type 1 diabetes, type 2 diabetes, and cystic fibrosis related diabetes. He was the Clinical Director for the Insulin-Only Bionic Pancreas Pivotal Trial, the results of which were published in the New England Journal of Medicine in September, 2022. He joined Beta Bionics in November, 2022.

His other projects have included evaluation of continuous glucose monitoring technology, methods for automated management of glucose in hospitalized patients, investigations of methods to improve insulin pharmacokinetics, and investigations of stable formulations of glucagon. Dr. Russell’s research has been supported by the National Institutes of Health (NIH), The Leona M. and Harry B. Helmsley Charitable Trust, the Banting Foundation, the American Diabetes Association, and the Juvenile Diabetes Research Foundation.

Professor, Division of Metabolism, Endocrinology and Nutrition
Director, Diabetes Research Center
University of Washington,
United States

Steven Kahn is a Professor of Medicine at the VA Puget Sound Health Care System and University of Washington in Seattle, Washington. He holds the Leonard L. Wright and Marjorie C. Wright Chair and directs the Diabetes Research Center at the University of Washington.

His research interests include the role of the ß-cell in the pathogenesis and treatment of prediabetes and type 2 diabetes. He has performed physiological studies and actively participates in a number of large multicenter clinical trials to prevent and treat type 2 diabetes, which includes studies comparing youth and adults. Aside from his clinical studies, he has an extensive basic research program examining the loss of ß-cells in type 2 diabetes.

He has received numerous awards including the Endocrine Society Clinical Investigator Award, Department of Veterans Affairs John B. Barnwell Award, European Association for the Study of Diabetes Albert Renold Award and Claude Bernard Lecture and Award, and the American Diabetes Association Outstanding Achievement in Clinical Diabetes Research Award.

MD
Hacettepe University School of Medicine, Ankara,
Turkey

Dr. Bulent O. Yildiz is a Professor of Medicine / Endocrinology and Metabolism at Hacettepe University School of Medicine, Ankara, Turkey. His clinical and research interests involve obesity, diabetes and androgen excess disorders in women including polycystic ovary syndrome. He has published over 140 original articles, reviews and book chapters, and delivered several presentations, lectures and conferences worldwide.

Dr. Yildiz was an Executive Committee Member and Officer of the European Society of Endocrinology and Board Member of Androgen Excess and PCOS Society. He chaired ECE 2017 and co-chaired ENDO 2021 and 2022. He currently serves as the Clinical Lead for the ESE Reproductive and Developmental Endocrinology Focus Area. He is the founder and president of the EndoBridge®, a unique international educational initiative supported by Endocrine Society and the European Society of Endocrinology.

His awards include the Distinguished Young Scientist Awards from Hacettepe University, Turkish Academy of Sciences, The Scientific and Technological Research Council of Turkey, Special Recognition Award by the European Society of Endocrinology, Walter Futterweit Clinical Research Excellence Award by the AE-PCOS Society and the Eisenhower Fellowship for international leadership from The Eisenhower Foundation of the United States. Fellowship of Dr. Yildiz focuses on the academia-government-industry relations on research, public policy and healthcare delivery for the prevention and management of chronic diseases, specifically diabetes and obesity.

MD, MACP
Division of Endocrinology, Diabetes, and Metabolism
Johns Hopkins University School of Medicine
United States

David S. Cooper, MD, MACP is a graduate of the Tufts University School of Medicine, and completed his endocrinology training at Massachusetts General Hospital and Harvard Medical School. He is currently Professor of Medicine and Radiology at the Johns Hopkins University School of Medicine, and Professor of International Health at the Bloomberg Johns Hopkins School of Public Health. He is one of the editors of the iconic textbook on thyroid disease, Werner and Ingbar’s The Thyroid, and he co-edits two other textbooks: Medical Management of Thyroid Disease and Thyroid Cancer. He is also the co-author of a book for patients with thyroid disease entitled Your Thyroid: A Home Reference. He is the past Chair of the Subspecialty Board for Endocrinology, Diabetes, and Metabolism of the American Board of Internal Medicine. He is an Editor-in-Chief for Endocrinology at Up-to-Date, and he has served as the Chair of the Endocrine Society’s annual Board Review Course. Dr. Cooper was the Chair of the American Thyroid Association’s (ATA) 2006 and 2009 task forces that first drafted clinical practice guidelines for the management of thyroid nodules and thyroid cancer. He also served on ATA sponsored task forces that promulgated guidelines for the management of hypothyroidism and for the management of hyperthyroidism. He is the past Treasurer and past President of the ATA, and the recipient of the ATA’s.

MB BS and MD (Qld) FRACP
Head of Mater Clinical Unit University of Queensland Pre eminent Endocrinologist
Director of Obstetric Medicine Mater Health Services Brisbane Australia
Honorary Skou Professor Aarhus University, Denmark
Australia

Professor David McIntyre trained in Endocrinology in Australia and Belgium. He is Director of Obstetric Medicine at Mater Health Services and Head of the Mater Clinical Unit for the University of Queensland.

David has published over 210 papers (>24,000 citations), primarily in the field of medical complications of pregnancy, with a particular focus on diabetes and obesity. Recent research has examined the effects of diabetes, obesity and hypertension during pregnancy on the health of Mothers and Babies, during pregnancy and with long term follow up.

In 2016, David became the first Australian trained clinician to receive the Norbert Freinkel Award for diabetes in pregnancy from the American Diabetes Association. In 2019 he was awarded both the Jørgen Pedersen Lecture by DPSG Europe and the Award Lecture for “Diabetes and Women” by the International Diabetes Federation.

David is a Past President of ADIPS and is currently a member of the FIGO Pregnancy and long term health committee. He is and Board Member and the Immediate Past Chair of IADPSG.

Canada

Harpreet Singh Bajaj is an Endocrinologist and Medical Director of Endocrine & Metabolic Research at LMC Healthcare/Centricity Research in Canada. Dr Bajaj completed his endocrinology fellowship at the Cleveland Clinic (Ohio, USA). Dr Bajaj’s medical education was at University of Delhi, India, followed by a Masters of Public Health (Epidemiology) at State University of New York in Albany (New York, USA).

Dr. Bajaj is a Research Associate at Mount Sinai Hospital, Toronto and an adjunct lecturer at McMaster University. He has co-authored publications in key medical journals in the fields of diabetes prevention and management, obesity and cardiovascular risk reduction.

He is the Principal Investigator of the Canadian Diabetes Prevention Program, a nationwide collaborative effort between LMC, Diabetes Canada with the Public health agency of Canada. Dr. Bajaj currently serves Diabetes Canada as the Chair of the Clinical Practice Guidelines Steering Committee.

BA, MB.B.Chir, MD, MA, FRCP

Royal Liverpool University Hospital/University Of Liverpool, AstraZeneca, UK

United Kingdom

Jiten Vora is a Consultant Physician/ Professor at the Liverpool University Hospitals and the University of Liverpool. Professor Vora has also been Chief Medical Advisor for Cardiovascular and Metabolic Diseases at AstraZeneca, 2015-2019. He qualified at the University of Cambridge, before completing substantive training in diabetes and endocrinology at the University of Wales College of Medicine. He was also a Fulbright Senior Fellow at Oregon Health Sciences University, Portland, USA

Professor Vora has research interests in the development, screening, and treatment of diabetic retinopathy, in renal hemodynamics and hypertension in Type 2 diabetes, in the prevention of renal diseases in diabetes, in the physiological aspects of treatment of Type 2 diabetes, and in mechanisms of osteoporosis. He has published extensively in the field of diabetes, and co-authored several textbooks concerning the management of diabetes.

United States

M.D, PhD

Denmark

Lars Krogvold, M.D., PhD is a consultant in paediatric diabetology and endocrinology at the Children department, Oslo University Hospital, Norway. He is also associate professor in paediatrics at the Faculty of Odontology, University of Oslo. He has been member of the Executive committee as treasurer in the International Society for Pediatric and Adolescent Diabetes (ISPAD) since 2018. In diabetic research, he finished his PhD-degree in 2016 entitled “The pathogenesis of type 1 diabetes - lessons from pancreatic biopsies in the Diabetes Virus Detection Study (DiViD)”, which thoroughly described pancreatic biopsies from newly diagnosed type 1 diabetic adult patients. The collected material has so far led to more than 45 peer-reviewed articles, in close collaboration with researcher all over the world. Krogvold is currently working 50% as a consultant and 50% as postdoctoral researcher at the University of Oslo. At present, he is the project manager of the DiViD intervention study, which is a randomized controlled trial where children with new-onset T1D are treated with anti-viral medications or placebo, as an attempt to better preserve endogenous insulin production.

Professor in Medicine,
Integrative Physiology,
Director, Pituitary Adrenal and Neuroendocrine Tumor Program
University of Colorado Anschutz Medical Campus
Staff Physician and Investigator, Rocky Mountain Regional VAMC
United States

Margaret E. Wierman MD, is a Professor of Medicine, Integrative Physiology at the University of Colorado School of Medicine. She directs the Pituitary and Adrenal Tumor Program. Dr. Wierman is a translational physician scientist whose research interest has been in reproductive endocrinology and sex hormone action, and more recently in the molecular mechanisms of pituitary tumors and adrenal cancer. She also directs the Program to Advance Gender Equity in the Department of Medicine. Dr. Wierman has a long track record in mentoring and pipeline development of academic researchers. She directs the K to R grant review and mock study section program at Colorado to aid junior investigators in obtaining their first R type award. She received the Women in Endocrinology Mentor Award and the Endocrine Society Laureate Mentor Award from the Endocrine Society. Dr. Wierman is the chair-elect for the International Society of Endocrinology.

MD, FACE
Professor of Medicine and Neurological Surgery and
Director of the Pituitary Center
Oregon Health and Science University in Portland, Oregon, USA
Past President of the Pituitary Society
United States

Dr. Fleseriu has a long-standing clinical and research interest in the pathophysiology and treatment of pituitary and adrenal disorders. She has received several awards, title of “Doctor Honors Causa” by the University of Medicine and Pharmacy “Carol Davila” and the Clinical Endocrinology Trust Award from the Society of Endocrinology. She is a frequent plenary guest speaker at national and international meetings and is Deputy Editor for European Journal of Endocrinology, Associate Editor for Reviews of Endocrinology and Metabolism and a member in many editorial boards, including Pituitary. Dr. Fleseriu has been global principal investigator in many pituitary disorders clinical trials and has authored over 200 manuscripts in prestigious journals, including novel treatments, international guidelines and consensus papers for Cushing’s, acromegaly and hypopituitarism.

Professor Neil Gittoes BSc MBChB PhD FRCP
Head, Centre for Endocrinology, Diabetes and Metabolism
Consultant Endocrinologist and Honorary Professor of Endocrinology
United Kingdom

Professor Neil Gittoes is Consultant and Honorary Professor of Endocrinology at the University of Birmingham and he is Head of the Centre of Endocrinology, Diabetes and Metabolism (CEDAM). He leads the metabolic bone diseases unit in Birmingham, and a number of national work streams through the Royal Osteoporosis Society as Chair of the Board of Trustees and as National Clinical Lead for Specialised Endocrinology, NHSEI. Neil is member of the National Osteoporosis Guideline Group (NOGG); he works with NICE and was Clinical Lead for NICE Guideline on Primary Hyperparathyroidism (NG132) and instigated Rapid Evidence Summary for vitamin D in COVID-19 (ES28). He is member and co-chair of the International Taskforce and European PARAT programme on parathyroid disorders. He was honoured by the Royal College of Physicians and made Goulstonian Lecturer for his contributions to clinical research. He has published more than 150 papers, reviews and chapters across endocrinology, focussing on bone and mineral metabolism. His clinical research interests include models of fracture prevention, rare causes of fracture susceptibility and disorders of calcium homeostasis.

Professor of Medicine
Consultant Endocrinologist
Director RCSI Clinical Research Centre
Ireland

Professor Sherlock graduated from the Royal College of Surgeons in Ireland in 2000 and undertook his specialist endocrine training initially in Beaumont Hospital. Following this he received specialist training in Endocrinology in the Queen Elizabeth Hospital, Birmingham and University of Birmingham, where he spent five years. He received his MD thesis for studies related to morbidity and mortality in patients with acromegaly. He obtained his PhD thesis from the University of Birmingham for studies relating to cortisol metabolism in muscle and in patients receiving hydrocortisone therapy. Professor Sherlock is author of more than 100 peer reviewed publications and 6 book chapters. He is an Associate Editor of the Journal of Clinical Endocrinology and Metabolism.

Professor Sherlock is Professor of Medicine in the Royal College of Surgeons and a Consultant Endocrinologist in Beaumont Hospital, Dublin. He is also Director of the Royal College of Surgeons in Ireland Clinical Research Centre. Professor Sherlock’s main clinical and research interests are in pituitary and adrenal disease and salt and water homeostasis.

Professor of Endocrinology, Chair of Medical Department IV
Ludwig-Maximilians University in Munich
Germany

The Medical Department IV is part of Ludwig-Maximilians University, one of the leading institutions in German academic medicine. His research specialities include endocrine hypertension including primary aldosteronism, Cushing’s syndrome, pituitary and adrenal diseases. Professor Reincke is heading a research team specifically exploring the prevalence and relevance of mineralocorticoid excess in resistant hypertension on the epidemiological, clinical, genetic and molecular level. Professor Reincke is a member of many national and international societies, including the Endocrine Society, European Society of Endocrinology and European Network of the study of adrenal tumors. He has served in the Executive Board of the German Endocrine Society and European Society of Endocrinology, is on the editorial board of several international journals, has served as teaching dean of the faculty from 2006-2012, and as president of the German Endocrine Society (2014-2017). Prof. Reincke won the prestigious European Research Council Advanced Grant Award (2.5 Mio €) in 2016. He is president of the European Society of Endocrinology. His publication include more than 580 Medline listed manuscripts, cited >18.600 times, his h-index is 69.

Sweden

Paul has led the design and implementation of major international initiatives focusing on developing and implementing precision healthcare. Paul is passionate about developing precision healthcare solutions for low and middle income countries. Prior to transitioning to philanthropy in 2021, Paul’s research focused on interactions between host genetics and environmental catalysts in cardiometabolic disease. He has a strong background in biostatistics and genetic and molecular epidemiology. Paul has coauthored ~500 peer reviewed papers, many in leading journals (see below). His H-Index is 116 and he is ranked amongst the world’s most highly-cited researchers.

Paul is currently Director of the division of Translational Medicine at the Novo Nordisk Foundation (Copenhagen, Denmark), the world’s largest private foundation. He is an Adjunct Professor at the Harvard School of Public Health (Boston, MA), Professor of Genetic Epidemiology at Lund University (Sweden), and a Visiting Professor of Diabetes and Metabolism at the University of Oxford (UK). He was formerly Deputy Director of Lund University Diabetes Center (2016-2021) (~350 scientists/staff) one of the world’s premier diabetes research institutes.

Paul is currently Director of the division of Translational Medicine at the Novo Nordisk Foundation (Copenhagen, Denmark), the world’s largest private foundation. He is an Adjunct Professor at the Harvard School of Public Health (Boston, MA), Professor of Genetic Epidemiology at Lund University (Sweden), and a Visiting Professor of Diabetes and Metabolism at the University of Oxford (UK). He was formerly Deputy Director of Lund University Diabetes Center (2016-2021) (~350 scientists/staff) one of the world’s premier diabetes research institutes.

Paul trained at the University of Cambridge (1999-2003) and the U.S. National Institutes of Health (2003-2005).

OBE FRCP PhD
United Kingdom

Professor Rachel Batterham is Professor of Obesity, Diabetes and Endocrinology at University College London (UCL)and Honorary Consultant at University College London Hospital (UCLH) She is the Clinical Director for the Division of Medicine at UCL, Director for the UCLH/UCL NIHR Biomedical Research Centre Obesity Research Theme and leads the UCL Centre for Obesity Research. She is the Royal College of Physicians’ Special Advisor on Obesity.

In 2022 she was awarded the honour of Officer of the Order of the British Empire (OBE) by the late HM Queen Elizabeth II for her services to people affected by obesity. She has also received several national and international awards for her obesity research including the Royal Society of Medicine’s Steven’s Lecture (2018), the Andre Mayer award from the World Obesity Federation (2016), and the Diabetes UK Rank Fund Nutrition Prize (2015). Her research has played a critical role in gut hormones being developed as treatments for obesity (Nature 2002, NEJM 2003, Nature 2007, JCI 2013, Diabetes 2020, NEJM 2021, Lancet 2021) and her papers have been cited >25,000.

Professor Batterham has made significant clinical contributions to defining the management of patients living with obesity through her membership of the NICE Obesity Guideline Development Group. She is co-chair of NHS England’s Clinical Advisory Group for specialist weight management, a Trustee for the Association for the Study of Obesity (since 2016) Council Member for British Obesity and Metabolic Surgery Society (since 2016), Member of the National Bariatric Surgery Registry Committee. She is passionate about reducing the stigma that people with obesity experience and ensuring that the patient voice is heard and has established a charity for people affected by obesity, Obesity Empowerment Network UK.

Cardiac Surgeon
St Michael’s Hospital of Unity Health Toronto Scientist
Keenan Research Centre for Biomedical Science and Li Ka Shing
Knowledge Institute of Unity Health Toronto
Professor of Surgery and Pharmacology & Toxicology
University of Toronto Canada Research Chair in Cardiovascular Surgery
Canada

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr Verma is a Fellow of the Canadian Academy of Health Sciences, one of the highest national honours that recognizes scholars for their promotion of health science. In 2022, Dr Verma was named a Clarivate Highly Cited Researcher in Clinical Medicine. In 2021, he was bestowed the University of Toronto Lister Prize in Surgery in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research from the International Academy of Cardiovascular Sciences and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. Dr Verma is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the Royal Society of Canada College of New Scholars, Artists and Scientists.

Dr Verma’s over 500 peer-reviewed publications have earned him a Google Scholar h-index of 115 with nearly 60,000 citations. He has published extensively in highly impactful journals like the NEJM, Lancet, Nature, Circulation, European Heart Journal and JACC. He is an Associate Editor of the European Heart Journal and a Section Editor of Current Opinion in Cardiology. Dr Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was also a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr Verma is the current Scientific Program Committee Chair for the Canadian Society of Cardiac Surgeons and has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma had/has leadership roles in multiple contemporary global heart failure trials – several of which persuaded guideline writing committees to recommend paradigm changes in how individuals who live with heart failure should be managed. He founded the CardioLink platform at St Michael’s Hospital that united cardiac surgeons from across Canada to conduct robust clinical trials to better inform on surgical decisionmaking pathways. CardioLink has since expanded its scope to include cardiometabolic studies.

Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiometabolic diseases. His current research is centred around modulating vascular regenerative cell exhaustion to alleviate cardiometabolic risk. Dr Verma holds 2 United States patents, and his research program is supported by national peerreviewed grants.

MD MPH FACG, FACP, AGAF, FAASLD Falls Church

United States

Zobair M Younossi is the President of Inova Medicine as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Falls Church, Virginia, USA. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY, USA. He then completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, USA, while earning his master of public health degree with multiple honours from San Diego State University School of Public Health, San Diego, California, USA. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, USA, before establishing the Canter for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President and Chairman of Research for Inova Health System (2010-2022). He also serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation (2018-Present) and the Board of Inova Health System Foundation (2011-Present). He was appointed by Governors T Kaine and B McDonnell of Virginia to the Board of Directors of Virginia Biotechnology Research Partnership Authority (2008-2014). He also served Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors, America Heart Association, Mid-Atlantic Affiliate (2010-2012) and Board of the American College of Gastroenterology Institute for Clinical Research & Education (2013-2019). Finally, he has served on multiple committees for American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastrointestinal Association and George Mason University as well as numerous committees at Inova Fairfax Medical Campus and Inova Health System.

Over the past 3 decades, Dr.Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and outcomes research in liver disease. He leads several international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of the Global NASH Council and the Global Liver and NASH Registries as well as Serving as the President and Chairman of the Board of Trustees of Chronic Liver Foundation. Dr.Younossi specializes in hepatology and gastroenterology, has authored over 700 articles, 3 books, 6 journal supplements, over 25 book chapters and over 1000 abstracts presented at the international scientific meetings and has an H-index of 105. He is highly sought-after speaker and has provided over 480 faculty lectures in national and international meetings. Dr.Younossi has also served as the co-editor of Liver International, Associate Editor of J of Hepatology and on the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Diplomat American Board of Internal Medicine,
Diplomat American Board of Diabetes, Endocrinology and Metabolism
Pakistan

Dr. S. Abbas Raza is working as consultant Diabetologist /Endocrinologist. Dr. Raza graduated from Allama Iqbal Medical College, Lahore Pakistan. He received his Internal Medicine residency training and Fellowship training for Diabetes, Endocrinology and Metabolism in USA. He served as a Chief Resident at Atlantic City Medical College, USA and Fellowship / investigator at University of Wisconsin, Madison, U.S.A.

Dr. Raza is American Board certified in Internal Medicine and has specialty American board in Diabetes , Endocrinology and Metabolism.

Dr. Raza has been honored with Fellowship by American College of Endocrinology and Sri Lanka College of Endocrinologists.

Dr. Abbas Raza currently holds the honor of being first Asian to serve as President of the International Society of Endocrinology (ISE), which is an International Society working for promotion of science of Endocrinology.

He has also served as President of organizations including South Asian Federation of Endocrine Societies (SAFES) (First Pakistani) / Pakistan Endocrine Society (PES) and American Association of Clinical Endocrinologist (AACE) – Pakistan Chapter (Founder – First President).

Dr. Raza has been awarded “Lifetime Achievement award” by Pakistan Endocrine Society due to his contribution as a researcher and prolific writer of scientific papers / research apers / regional – International Guidelines disease management guidelines and book chapters.

Dr. Raza Innovation in Diabetes management include his “Dream Diabetes” project. This project takes Diabetes management to doorstep of underprivileged population suffering from Diabetes. This caters to needs of patient living in underdeveloped areas and do not have access to specialist care.

Dr. Raza philanthropic works includes responsibilities in “Friend Of Mayo” (FOM) and Dilawar Hussain Foundation (DHF). FOM works for upgrading Mayo Hospital, which is a century old hospital, catering for poor / non affording patients. While Dilawar Hussain Foundation, is a social welfare & charity organization serving in the field of health, education, and community awareness. DHF runs Charity Diabetes Clinics and caters to thousands of patient suffering with Diabetes and unable to afford treatment.